A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression

D. Li, S. Pant, D. P. Ryan, D. Laheru, N. Bahary, T. Dragovich, P. J. Hosein, L. Rolfe, M. W. Saif, J. Lavalle, K. H. Yu, M. A. Lowery, A. Allen, E. M. O'Reilly

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression'. Together they form a unique fingerprint.

Medicine & Life Sciences